Givosiran clinical trials
Also written GIVLAARI and ALN-AS1.
How each study uses givosiran is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- 20 Nov 2019 · GIVLAARI · NDA 212194 (FDA, Drugs@FDA)
- European Union
- 2 Mar 2020 · Givlaari · EMEA/H/C/004775 (EMA)
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
4 studies that test it; most in 2015 (1)
| Year | Studies |
|---|---|
| 2015 | 1 |
| 2016 | 1 |
| 2017 | 1 |
| 2018 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 4 · Other 0
Studies
Open first, then newest update. How each study uses givosiran is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 4
- ENVISION: A Study to Evaluate the Efficacy and Safety of Givosiran (ALN-AS1) in Patients With Acute Hepatic Porphyrias (AHP)CompletedPhase 3Alnylam PharmaceuticalsNCT03338816Written as GivosiranHow we know
- A Study to Evaluate Long-term Safety and Clinical Activity of Givosiran (ALN-AS1) in Patient With Acute Intermittent Porphyria (AIP)CompletedPhase 1/2Alnylam PharmaceuticalsNCT02949830Written as GivosiranHow we know
- A Study to Investigate the Interaction Between Givosiran and a 5-probe Drug Cocktail in Patients With Acute Intermittent Porphyria (AIP)CompletedPhase 1Alnylam PharmaceuticalsNCT03505853Written as GivosiranHow we know
- A Phase 1 Study of Givosiran (ALN-AS1) in Patients With Acute Intermittent Porphyria (AIP)CompletedPhase 1Alnylam PharmaceuticalsNCT02452372Written as givosiran (ALN-AS1)How we know
Codes
What other systems call givosiran · ClinicalTrials.gg INT001060
- MeSH (NLM) C000630124givosiranOne source NLM
- UNII (FDA) ROV204583WGIVOSIRANConfirmed FDA, NLM, Wikidata
- RxNorm 2265712Confirmed FDA, Wikidata
- Wikidata Q56297041givosiranConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C146805GivosiranOne source FDA
- DrugBank DB15066One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C000630124 | givosiran | One source NLM |
| UNII (FDA) | ROV204583W | GIVOSIRAN | Confirmed FDA, NLM, Wikidata |
| RxNorm | 2265712 | — | Confirmed FDA, Wikidata |
| Wikidata | Q56297041 | givosiran | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C146805 | Givosiran | One source FDA |
| DrugBank | DB15066 | — | One source Wikidata |
Also registered as givosiran sodium (UNII 5XE21E41RT · RxNorm 2265859).
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.